Loading...

Laxxon Medical owns the exclusive worldwide rights for the development, production and commercialization of innovative drug delivery systems on the basis of a worldwide patented large-scale 3D screen printing technology (SPID®-Technology).

Compared to traditional drug delivery systems the benefits of Laxxon’s technology lies in (i) improvement of the pharmacokinetics of APIs and thus improved bioavailability, (ii) enhancement of the solubility, (iii) the reduction of adverse side effects and (iv) improvement of patient compliance.

3D screen printing is a proprietary additive manufacturing technology. It enables custom geometry, size, inner architecture allowing discontinuous distribution of active pharmaceutical ingredient(s) (API) within in given dosage form, and therefore offers high flexibility with regard to dosing and tailoring of drug release profiles. 3D screen printing uses a screen mesh to transfer a semi-solid, API-containing paste onto a plate, except in areas made impermeable to the paste. The deposited layer is then dried. The next layer is printed precisely on top of the previous one after lifting the screen by the dried layer thickness. Screen printing has the potential for mass customization enabling the build-up of thousands of units per screen simultaneously. The number of units printed simultaneously is largely defined by the ratio of screen size to unit size. This differentiates screen printing from other 3DP technologies, whose capacity is limited by the number of printing heads.

3D screen printing, a fully automated technology, adds the third dimension to the classical form of screen printing. It offers high freedom in choice of materials. Material is only added where structures are being built-up. Thickness of walls (X-Y dimensions) spans from 50µm to several centimeters. Bank heights range from 10µm to several centimeters. Single layers vary in thickness from 10µm to 100µm (screen) and beyond (pattern).

The manufacturing process is divided into two phases:

  • Preparation of the paste and the printing unit
  • Printing process itself

The first phase encompasses:

  • Development and preparation of the printing paste
  • Design and selection of screen
  • Selection of appropriate squeegees and printing plate

The 3D printing process consists of a series of distinct operations (Figure 1)

  • Application of the printing paste onto the printing screen, which is then drawn over the screen by a squeegee and fills the meshes in the screen; a second squeegee presses the paste through the meshes of the screen onto the printing plate
  • Screen is lifted up and printing plate moves from the printing station to curing station (e.g., drying by convection at defined temperatures; infrared radiation)
  • Layer is being dried
  • Platform returns to printing station
  • The next cycle starts by height adjustment of the printing plate, followed by the application of the next layer

The cycle is repeated until the geometry of the device is completed. The type of drying (thermal convection (standard), IR radiation, etc.) is driven by the materials used and can be varied as needed.

Figure 1: Schematic representation of the 3D screen printing process

Enables mass-production (up to 1.5MM units per day) of tablets, film, implants, transdermal patches with novel drug formulations, galenic and novel geometric structures

Cold-pressure process, enables wide range of API`s

Printing speeds significantly faster than for established 3D printing processes

Innovation of improved drug delivery for established APIs generates opportunities for new patents on improved DDS

Company operates its application lab and ordered its first 3D production unit capable of mass production under GMP (Good Manufacturing Practice).

Loading...

Clinical Improvements

  • Tailoring of Pharmacokinetics
  • Improved Bioavailability
  • Optimization of Side Effects
  • Improves Patient Compliance

Drug Delivery Innovations

  • High-precision release profiles for oral tablets and pills – fast onset of action up to longlasting retarding effects
  • Mucoadhesive and peroral dosage forms
  • Multiple API combinations in one DDS
  • Reduction of multiple daily dosages to one

Clinical Improvements

  • Tailoring of Pharmacokinetics
  • Improved Bioavailability
  • Optimization of Side Effects
  • Improves Patient Compliance

Drug Delivery Innovations

  • High-precision release profiles for oral tablets and pills – fast onset of action up to longlasting retarding effects
  • Mucoadhesive and peroral dosage forms
  • Multiple API combinations in one DDS
  • Reduction of multiple daily dosages to one
Loading...